Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and… Read more
Kyntra Bio, Inc. (KYNB) - Total Liabilities
Latest total liabilities as of September 2025: $119.53 Million USD
Based on the latest financial reports, Kyntra Bio, Inc. (KYNB) has total liabilities worth $119.53 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kyntra Bio, Inc. - Total Liabilities Trend (2012–2024)
This chart illustrates how Kyntra Bio, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kyntra Bio, Inc. Competitors by Total Liabilities
The table below lists competitors of Kyntra Bio, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Canadian Banc Corp
PINK:CNDCF
|
USA | $385.42 Million |
|
CYBERAGENT (CL2.SG)
STU:CL2
|
Germany | €281.48 Billion |
|
Argentum Silver Corp
PINK:AGSVF
|
USA | $380.73K |
|
BIOCRYST PHARM
MU:BO1
|
Germany | €959.82 Million |
|
A S CREATION TAP N - Dusseldorf Stock Exchang
DU:ACWN
|
Germany | €41.99 Million |
|
Syncona Limited
LSE:SYNC
|
UK | GBX13.77 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Kyntra Bio, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -7.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kyntra Bio, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kyntra Bio, Inc. (2012–2024)
The table below shows the annual total liabilities of Kyntra Bio, Inc. from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $398.16 Million | -32.02% |
| 2023-12-31 | $585.73 Million | -4.23% |
| 2022-12-31 | $611.57 Million | +12.27% |
| 2021-12-31 | $544.71 Million | +41.34% |
| 2020-12-31 | $385.39 Million | +19.69% |
| 2019-12-31 | $321.99 Million | -8.56% |
| 2018-12-31 | $352.13 Million | +11.36% |
| 2017-12-31 | $316.20 Million | +7.39% |
| 2016-12-31 | $294.44 Million | +7.56% |
| 2015-12-31 | $273.75 Million | +12.72% |
| 2014-12-31 | $242.85 Million | +28.26% |
| 2013-12-31 | $189.35 Million | +32.04% |
| 2012-12-31 | $143.40 Million | -- |